WGRX: recent financing gives runway into late‑2026; lock-up leaves ~1.3M shares tradable; warrants could fund to 2029

Wellgistics says a recent capital raise and debt restructuring provides capital into late 2026, includes embedded warrants that, if exercised, would provide funding through 2029, and a lock-up limits freely tradable common shares to about 1.3 million. New shares from that financing will not be eligible for resale until issued and registered or eligible under Rule 144 (the company expects resale registration effectiveness in Q3 2026), and the company cannot issue shares for capital-raising until the earlier of seven months from the transaction date and 30 days after effectiveness of the resale registration statement. The company reiterated the DelivMeds AI and QOLPOM transactions are expected to close in Q3 2026 but remain subject to customary closing conditions. Timing: Public-market dilution depends on another filing or resale step first, and the press release does not say when that will be completed.

Filing Context